FIELD: medicine.
SUBSTANCE: what is presented is a therapeutic agent possessing antidepressant and stress-relieving action. The agent represents 9-[2-(4-isopropylphenoxy)ethyl]adenine distinguished for its anti-viral activity.
EFFECT: what is developed is psychotropic agent able to inhibit stress-inducing morphosomatic, cognitive and psychoemotional disorders, as well as possessing autonomous antidepressant activity.
14 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
| QUINAZOLINE DERIVATIVES, POSSESSING NOOTROPIC AND ANTIHYPOXIC ACTIVITY | 2012 |
|
RU2507198C1 |
| QUINAZOLINE DERIVATIVES, POSSESSING ANTIDEPRESSANT, ANXIOLYTIC AND NOOTROPIC ACTIVITY | 2012 |
|
RU2507199C1 |
| AGENT POSSESSIVE CARDIOPROTECTIVE ACTION UNDER STRESS STIMULATION | 2013 |
|
RU2531082C1 |
| ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
| AGENT POSSESSING CARDIOPROTECTIVE, ANTIPLATELET, ANTICOAGULANT AND MEMBRANE-PROTECTIVE PROPERTIES UNDER STRESS STIMULATION | 2013 |
|
RU2531080C1 |
| ANTIDEPRESSANT AGENT | 2018 |
|
RU2741938C2 |
| ANXIOLYTIC AND CEREBROPROTECTIVE AGENT REDUCING INCLINATION TO ALCOHOL | 2008 |
|
RU2393855C1 |
| PEPTIDE FOR TREATMENT OF ALZHEIMER'S DISEASE | 2017 |
|
RU2678987C2 |
| METHOD OF CORRECTING DISORDERS OF IMMUNE AND PSYCHOEMOTIONAL STATUS OF ORGANISM IN EXPERIMENTAL INFORMATION STRESS | 2010 |
|
RU2432949C1 |
